JP4794432B2 - キメラポリペプチドおよびその使用 - Google Patents

キメラポリペプチドおよびその使用 Download PDF

Info

Publication number
JP4794432B2
JP4794432B2 JP2006505169A JP2006505169A JP4794432B2 JP 4794432 B2 JP4794432 B2 JP 4794432B2 JP 2006505169 A JP2006505169 A JP 2006505169A JP 2006505169 A JP2006505169 A JP 2006505169A JP 4794432 B2 JP4794432 B2 JP 4794432B2
Authority
JP
Japan
Prior art keywords
dna
cell
cells
activity
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006505169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523448A (ja
JP2006523448A5 (https=
Inventor
クリスティアン・キューネ
アンドラシュ・シモンチトシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adriacell SpA
Original Assignee
Adriacell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adriacell SpA filed Critical Adriacell SpA
Publication of JP2006523448A publication Critical patent/JP2006523448A/ja
Publication of JP2006523448A5 publication Critical patent/JP2006523448A5/ja
Application granted granted Critical
Publication of JP4794432B2 publication Critical patent/JP4794432B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
JP2006505169A 2003-04-18 2004-04-16 キメラポリペプチドおよびその使用 Expired - Fee Related JP4794432B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2003A000821 2003-04-18
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
PCT/EP2004/004062 WO2004092194A2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011051784A Division JP2011182792A (ja) 2003-04-18 2011-03-09 キメラポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2006523448A JP2006523448A (ja) 2006-10-19
JP2006523448A5 JP2006523448A5 (https=) 2007-06-07
JP4794432B2 true JP4794432B2 (ja) 2011-10-19

Family

ID=33187374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006505169A Expired - Fee Related JP4794432B2 (ja) 2003-04-18 2004-04-16 キメラポリペプチドおよびその使用
JP2011051784A Pending JP2011182792A (ja) 2003-04-18 2011-03-09 キメラポリペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011051784A Pending JP2011182792A (ja) 2003-04-18 2011-03-09 キメラポリペプチドおよびその使用

Country Status (16)

Country Link
US (3) US20060292629A1 (https=)
EP (1) EP1616011B1 (https=)
JP (2) JP4794432B2 (https=)
KR (2) KR101360781B1 (https=)
CN (1) CN100584950C (https=)
AT (1) ATE374826T1 (https=)
AU (1) AU2004230254B2 (https=)
CA (1) CA2522525A1 (https=)
CY (1) CY1107115T1 (https=)
DE (1) DE602004009301T2 (https=)
DK (1) DK1616011T3 (https=)
ES (1) ES2293247T3 (https=)
IT (1) ITMI20030821A1 (https=)
PL (1) PL1616011T3 (https=)
PT (1) PT1616011E (https=)
WO (1) WO2004092194A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
ATE464395T1 (de) * 2005-02-18 2010-04-15 Astrazeneca Ab Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
CA2939694A1 (en) 2014-02-17 2015-08-20 Universite Claude Bernard Lyon 1 Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
CA3019629A1 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
WO2017205852A2 (en) * 2016-05-27 2017-11-30 Synthex, Inc. Protein interfaces
WO2017211941A1 (en) * 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein b
CA3067382A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
KR102503130B1 (ko) 2017-10-27 2023-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023111213A1 (en) 2021-12-16 2023-06-22 Rdp Pharma Ag Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535995A (ja) * 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
EP2806025B1 (en) * 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535995A (ja) * 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復

Also Published As

Publication number Publication date
CY1107115T1 (el) 2012-01-25
US20150018409A1 (en) 2015-01-15
JP2006523448A (ja) 2006-10-19
EP1616011B1 (en) 2007-10-03
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
US20060292629A1 (en) 2006-12-28
KR20110074948A (ko) 2011-07-04
WO2004092194A3 (en) 2005-03-17
EP1616011A2 (en) 2006-01-18
CN1768142A (zh) 2006-05-03
DE602004009301D1 (de) 2007-11-15
KR101360781B1 (ko) 2014-04-24
ES2293247T3 (es) 2008-03-16
KR20060003029A (ko) 2006-01-09
ATE374826T1 (de) 2007-10-15
KR101247704B1 (ko) 2013-03-26
US20110033384A1 (en) 2011-02-10
DK1616011T3 (da) 2008-02-04
ITMI20030821A1 (it) 2004-10-19
AU2004230254B2 (en) 2008-10-02
DE602004009301T2 (de) 2008-07-17
AU2004230254A1 (en) 2004-10-28
JP2011182792A (ja) 2011-09-22
CA2522525A1 (en) 2004-10-28
CN100584950C (zh) 2010-01-27
WO2004092194A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
JP2011182792A (ja) キメラポリペプチドおよびその使用
Zhang et al. 53BP1 regulates heterochromatin through liquid phase separation
Ceppi et al. Mechanism of BRCA1–BARD1 function in DNA end resection and DNA protection
Chen et al. The casein kinase II β subunit binds to Mos and inhibits Mos activity
Tomonaga et al. Characterization of fission yeast cohesin: essential anaphase proteolysis of Rad21 phosphorylated in the S phase
Aerts et al. PINK1 kinase catalytic activity is regulated by phosphorylation on serines 228 and 402
Kitagawa et al. The ATM-dependent DNA damage signaling pathway
Liku et al. CDK phosphorylation of a novel NLS-NES module distributed between two subunits of the Mcm2-7 complex prevents chromosomal rereplication
Tang et al. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis
Bouquet et al. The loss of γH2AX signal is a marker of DNA double strand breaks repair only at low levels of DNA damage
Macrae et al. APLF (C2orf13) facilitates nonhomologous end-joining and undergoes ATM-dependent hyperphosphorylation following ionizing radiation
Cassani et al. Tel1 and Rif2 regulate MRX functions in end-tethering and repair of DNA double-strand breaks
US20090280111A1 (en) Isolation of the Mitotic Spindle Matrix and its Methods of Use
Yu et al. Regulation of trafficking of activated TrkA is critical for NGF‐mediated functions
Desplancq et al. Targeting the replisome with transduced monoclonal antibodies triggers lethal DNA replication stress in cancer cells
Tulin et al. Mitotic entry is controlled by the plant-specific phosphatase BSL1 and cyclin-dependent kinase B
EP0966683B1 (en) Assays, agents, therapy and diagnosis relating to modulation of cellular dna repair activity
Sugaya et al. A temperature-sensitive mutation in the WD repeat-containing protein Smu1 is related to maintenance of chromosome integrity
Jaff Identification of Regions Required for CDCA7 Interaction with DNA Damage Repair Machinery
US20100297623A1 (en) NOVEL HUMAN ssDNA BINDING PROTEINS AND METHODS OF CANCER DIAGNOSIS
Bonalli Investigations on phosphospecific interactions in the DNA damage response
Lo Functional analysis of Cdc7 kinase activity reveals multiple roles in budding yeast meiosis
Fell The Role of the Ku70 vWA Domain in the Response to DNA Double Strand Breaks
Udayakumar Identification and characterization of two new players in DNA double-strand break repair: PSF and p54 (nrb)
Wu Roles of NBS1 and BRCA2 cancer susceptibility genes in the maintenance of genome stability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070416

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110726

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140805

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees